Total Funding
52
Total FundingVenture - Series Unknown raised
Growth Score
pts
Heat Score
-13 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
172491
AcuityBio is a commercialize novel polymer drug delivery technologies.
Jay Schwartz: CSO & President- Eyal S. Ron: Member Board of DirectorsPast Role: Gelesis, CTO (and Co-Founder)
About the Company
AcuityBio was founded by Mark Grinstaff, Ph.D., Alain Hanover, M.S., Jesse Wolinsky, Ph.D., and John 'Jay' Schwartz, Ph.D. in late 2009 to commercialize novel polymer drug delivery technologies to treat various types early stage, soft tissue cancers. AcuityBio's lead product candidate aimed at preventing the recurrence of non-small
cell lung cancer is based on a synthetic polymer technology invented by co-founders Professor Mark Grinstaff, Ph.D. and Jesse Wolinsky, Ph.D. at Boston University (BU), Departments of Biomedical Engineering and Chemistry. AcuityBio is a privately-held company based in the Greater Boston area.
